Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 Automated Instruments for Detection of Extended-Spectrum Beta-Lactamases in Multiresistant Escherichia coli and Klebsiella spp
Open Access
- 1 October 2002
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 40 (10) , 3703-3711
- https://doi.org/10.1128/jcm.40.10.3703-3711.2002
Abstract
Seventy-four isolates of multiresistant Escherichia coli and Klebsiella spp. recovered during a 3-year period and 17 control strains with genotypically identified beta-lactamases were tested for the production of extended-spectrum beta-lactamases (ESBLs) by using the Etest and the VITEK 1, VITEK 2, and Phoenix automated instruments. The use of the Etest was evaluated by investigating its accuracy in detecting the ESBLs of the control strains and by comparing interpretation results of laboratory technicians and experts. The accuracy of the Etest was 94%. With the Etest as the reference for the clinical strains and the genotype as the reference for the control strains, the automated instruments detected the ESBLs with accuracies of 78% (VITEK 2), 83% (VITEK 1), and 89% (Phoenix). No significant difference between the systems with regard to the control strains was detected. The VITEK 2 did, however, perform less well than the Phoenix ( P = 0.03) on the collection of clinical isolates, mainly because of its high percentage of indeterminate test results (11%). No significant difference between the performances of the VITEK 1 and either the VITEK 2 or the Phoenix was found. However, because of its associated BDXpert system the Phoenix showed the best performance. The Etest was found to be an accurate test but was limited by its indeterminate results (4%), its inability to differentiate between K1 hyperproduction and ESBLs, questionable guidelines concerning mutants inside the inhibition zones, and the inability of the technicians to recognize subtle zone deformations.Keywords
This publication has 42 references indexed in Scilit:
- Cefepime, Piperacillin-Tazobactam, and the Inoculum Effect in Tests with Extended-Spectrum β-Lactamase-Producing EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 2001
- Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganismsClinical Microbiology & Infection, 2001
- Validation of the VITEK2 and the advance expert system with a collection of enterobacteriaceae harboring extended spectrum or inhibitor resistant β-lactamasesDiagnostic Microbiology and Infectious Disease, 2001
- Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance ThreatClinical Microbiology Reviews, 2001
- Identification of a Plasmid Encoding SHV-12, TEM-1, and a Variant of IMP-2 Metallo-β-Lactamase, IMP-8, from a Clinical Isolate of Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2001
- Potential Impact of the VITEK 2 System and the Advanced Expert System on the Clinical Laboratory of a University-Based HospitalJournal of Clinical Microbiology, 2001
- Characterization of the Extended-Spectrum β-Lactamase Reference Strain, Klebsiella pneumoniae K6 (ATCC 700603), Which Produces the Novel Enzyme SHV-18Antimicrobial Agents and Chemotherapy, 2000
- Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inoculaThe Pediatric Infectious Disease Journal, 1997
- Ceftazidime-Resistant Klebsiella pneumoniae and Escherichia coli Bloodstream Infection: A Case-Control and Molecular Epidemiologic InvestigationThe Journal of Infectious Diseases, 1996
- Detection of genes coding for extended-spectrum SHV beta-lactamases in clinical isolates by a molecular genetic method, and comparison with the E testEuropean Journal of Clinical Microbiology & Infectious Diseases, 1996